## Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	A Phase III, multi-center, randomized, double-blind, non-inferiority study of Solithromycin versus Cefcapene pivoxil hydrochloride hydrate in patients with sinusitis
	Primary sponsor	Toyama Chemical Co., Ltd.
	Study Type	interventional (drug)
	Summary	To demonstrate non-inferiority of Solithromycin against Cefcapene pivoxil hydrochloride hydrate in patients with sinusitis
Details of study	Interventional drug name	Solithromycin (T-4288)
	Target illness	Sinusitis
	Classification name (code) of the investigational drug	614 (antibiotic preparations acting mainly on gram-positive bacteria and mycoplasma)
	Administration route	Oral Multiple Dose
	Control drug name(code/td)	Cefcapene pivoxil hydrochloride hydrate
	Classification name (code) of the investigational drug	613 (antibiotic preparations acting mainly on gram-positive gram-nagative bacteria)
	Administration route	Oral Multiple Dose
	Objectives of the study	To demonstrate non-inferiority of Solithromycin against Cefcapene pivoxil hydrochloride hydrate in patients with sinusitis
	Study phase	Phase 3
	Study design	Randomized, Multi-center, Double-Blind study
	Inclusion Criteria	Inclusion 1.Age: 20 years of age and older (at the time of obtaining informed consents) 2.Gender: Both
		3.Inpatient/Outpatient status: Outpatient
		4. Signed the informed consent form by patients
		5. Sinusitis with clear infection symptoms
		Exclusion
		1. Having improvement of clinical symptoms due to
		target disease by other systemic antibiotics
		2. Having a history of allergy to macrolide, penicillin or cephem antibiotics
		3.Others
	Outcome	efficacy and safety profile
	Study status	On going
	Duration of the study	-
	Region	Japan
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Clinical Planning Department
	Contact	Form for Inquiry https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn